Literature DB >> 6544917

The cellular protein p53 in human tumours.

L V Crawford, D C Pim, P Lamb.   

Abstract

Tumour tissue from patients with colorectal and mammary tumours has been assayed for the cellular protein p53 using a specific radioimmune assay. The levels of p53 in normal tissues are not detectable with this assay but a substantial number of the tumours showed detectable p53, i.e. the amounts of this protein were significantly increased, to levels which varied from 0.3% to 10% of that found in simian virus 80 (SV80), an SV40 transformed human fibroblast cell line. Sera from the same patients were also assayed for the presence of anti-p53 antibodies and found to be positive in about 12% of the patients. The presence of increased amounts of p53 is not peculiar to malignant tumours since 4 out of 19 fibroadenomas (benign breast tumours) showed detectable amounts of p53 protein. The DNA from tumours was examined by Southern blotting using a variety of restriction enzymes. The arrangement of the p53 gene was not detectably altered in comparison with that in normal human foetal liver DNA. No alteration was observed which could be correlated with the increased levels of p53 in the positive tumours.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6544917

Source DB:  PubMed          Journal:  Mol Biol Med        ISSN: 0735-1313


  37 in total

1.  Characterization of the human p53 gene promoter.

Authors:  S P Tuck; L Crawford
Journal:  Mol Cell Biol       Date:  1989-05       Impact factor: 4.272

Review 2.  p53, a translational regulator: contribution to its tumour-suppressor activity.

Authors:  V Marcel; F Catez; J-J Diaz
Journal:  Oncogene       Date:  2015-03-02       Impact factor: 9.867

3.  Clinicopathological findings and p53 expression of thyroid cancer in children.

Authors:  T Kobayashi; H Nakanishi; I Yana; I Nishisho; Y Itoh; E Wakasugi; T Takeda; T Mori
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

4.  Use of specific ELISA for the detection of antibodies directed against p53 protein in patients with hepatocellular carcinoma.

Authors:  S D Ryder; P M Rizzi; M Volkmann; E Metivier; L M Pereira; P R Galle; N V Naoumov; H Zentgraf; R Williams
Journal:  J Clin Pathol       Date:  1996-04       Impact factor: 3.411

5.  Characterization of the human p53 gene.

Authors:  P Lamb; L Crawford
Journal:  Mol Cell Biol       Date:  1986-05       Impact factor: 4.272

6.  Primary structure polymorphism at amino acid residue 72 of human p53.

Authors:  G J Matlashewski; S Tuck; D Pim; P Lamb; J Schneider; L V Crawford
Journal:  Mol Cell Biol       Date:  1987-02       Impact factor: 4.272

7.  Autoantibodies to tumor-associated antigens in breast carcinoma.

Authors:  Ettie Piura; Benjamin Piura
Journal:  J Oncol       Date:  2010-11-21       Impact factor: 4.375

8.  Antibodies against p53 protein in serum of patients with benign or malignant pancreatic and biliary diseases.

Authors:  P Laurent-Puig; R Lubin; S Semhoun-Ducloux; G Pelletier; C Fourre; M Ducreux; M J Briantais; C Buffet; T Soussi
Journal:  Gut       Date:  1995-03       Impact factor: 23.059

Review 9.  Tumor protein p53 (TP53) testing and Li-Fraumeni syndrome : current status of clinical applications and future directions.

Authors:  April D Sorrell; Carin R Espenschied; Julie O Culver; Jeffrey N Weitzel
Journal:  Mol Diagn Ther       Date:  2013-02       Impact factor: 4.074

Review 10.  Genomic and proteomic biomarkers for cancer: a multitude of opportunities.

Authors:  Michael A Tainsky
Journal:  Biochim Biophys Acta       Date:  2009-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.